BioCentury
ARTICLE | Company News

Tacere, Oncolys BioPharma deal

February 14, 2011 8:00 AM UTC

Tacere reacquired development and commercialization rights in Asia to its family of HCV compounds, including TT-033 and TT-034, after it and Oncolys mutually terminated a 2007 deal. Further terms were not disclosed (see BioCentury, Oct. 16, 2006). ...